+

WO2004008153A3 - Diagnostique et therapie des maladies associees au recepteur presume de neurotransmetteurs chez l'humain (pnr) - Google Patents

Diagnostique et therapie des maladies associees au recepteur presume de neurotransmetteurs chez l'humain (pnr) Download PDF

Info

Publication number
WO2004008153A3
WO2004008153A3 PCT/EP2003/007092 EP0307092W WO2004008153A3 WO 2004008153 A3 WO2004008153 A3 WO 2004008153A3 EP 0307092 W EP0307092 W EP 0307092W WO 2004008153 A3 WO2004008153 A3 WO 2004008153A3
Authority
WO
WIPO (PCT)
Prior art keywords
pnr
therapeutics
diagnostics
diseases
homo sapiens
Prior art date
Application number
PCT/EP2003/007092
Other languages
English (en)
Other versions
WO2004008153A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Priority to AU2003244637A priority Critical patent/AU2003244637A1/en
Publication of WO2004008153A2 publication Critical patent/WO2004008153A2/fr
Publication of WO2004008153A3 publication Critical patent/WO2004008153A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un PNR humain, associé aux maladies cardio-vasculaires, aux troubles du SNC, aux maladies hématologiques ou encore génito-urinaires. L'invention concerne aussi des dosages destinés à l'identification de composés utiles dans le traitement de maladies cardio-vasculaires, de troubles du SNC, de maladies hématologiques ou encore génito-urinaires. Elle concerne également des composés qui se lient et/ou activent ou inhibent l'activité de PNR ainsi que des compositions pharmaceutiques comprenant ces composés.
PCT/EP2003/007092 2002-07-16 2003-07-03 Diagnostique et therapie des maladies associees au recepteur presume de neurotransmetteurs chez l'humain (pnr) WO2004008153A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003244637A AU2003244637A1 (en) 2002-07-16 2003-07-03 Diagnostics and therapeutics for diseases associated with homo sapiens putative neurotransmitter receptor (pnr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02015619 2002-07-16
EP02015619.6 2002-07-16

Publications (2)

Publication Number Publication Date
WO2004008153A2 WO2004008153A2 (fr) 2004-01-22
WO2004008153A3 true WO2004008153A3 (fr) 2004-03-04

Family

ID=30011072

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/007092 WO2004008153A2 (fr) 2002-07-16 2003-07-03 Diagnostique et therapie des maladies associees au recepteur presume de neurotransmetteurs chez l'humain (pnr)

Country Status (2)

Country Link
AU (1) AU2003244637A1 (fr)
WO (1) WO2004008153A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1626057A1 (fr) * 2004-07-30 2006-02-15 F.Hoffmann-La Roche Ag Récepteurs du chimpanzé associés aux "trace amines"
US8632534B2 (en) 2009-04-03 2014-01-21 Angiodynamics, Inc. Irreversible electroporation (IRE) for congestive obstructive pulmonary disease (COPD)
US8903488B2 (en) 2009-05-28 2014-12-02 Angiodynamics, Inc. System and method for synchronizing energy delivery to the cardiac rhythm
US9895189B2 (en) 2009-06-19 2018-02-20 Angiodynamics, Inc. Methods of sterilization and treating infection using irreversible electroporation
US9700368B2 (en) 2010-10-13 2017-07-11 Angiodynamics, Inc. System and method for electrically ablating tissue of a patient
WO2012088149A2 (fr) 2010-12-20 2012-06-28 Virginia Tech Intellectual Properties, Inc. Électroporation à haute fréquence pour thérapie anticancéreuse
US9078665B2 (en) 2011-09-28 2015-07-14 Angiodynamics, Inc. Multiple treatment zone ablation probe
US9414881B2 (en) 2012-02-08 2016-08-16 Angiodynamics, Inc. System and method for increasing a target zone for electrical ablation
US12114911B2 (en) 2014-08-28 2024-10-15 Angiodynamics, Inc. System and method for ablating a tissue site by electroporation with real-time pulse monitoring
US10905492B2 (en) 2016-11-17 2021-02-02 Angiodynamics, Inc. Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039440A1 (fr) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Recepteur d'amines humaines
WO2001072839A2 (fr) * 2000-03-27 2001-10-04 Pe Corporation (Ny) Recepteurs couples aux proteines g humaines isolees, molecules d'acides nucleiques codant les proteines gpcr humaines, et utilisations correspondantes
WO2002034913A2 (fr) * 2000-10-24 2002-05-02 Pe Corporation (Ny) Recepteurs couples aux proteines g humains, isoles, molecules d'acide nucleique codant ces proteines humaines des recepteurs couples aux proteines g (gpcr), et leurs applications
WO2002061087A2 (fr) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques
WO2002099107A2 (fr) * 2001-06-07 2002-12-12 Bayer Aktiengesellschaft Regulation du recepteur ta5 humain
WO2002101043A2 (fr) * 2001-06-08 2002-12-19 Bayer Aktiengesellschaft Regulation du recepteur ta4 humain

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039440A1 (fr) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Recepteur d'amines humaines
WO2001072839A2 (fr) * 2000-03-27 2001-10-04 Pe Corporation (Ny) Recepteurs couples aux proteines g humaines isolees, molecules d'acides nucleiques codant les proteines gpcr humaines, et utilisations correspondantes
WO2002034913A2 (fr) * 2000-10-24 2002-05-02 Pe Corporation (Ny) Recepteurs couples aux proteines g humains, isoles, molecules d'acide nucleique codant ces proteines humaines des recepteurs couples aux proteines g (gpcr), et leurs applications
WO2002061087A2 (fr) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques
WO2002099107A2 (fr) * 2001-06-07 2002-12-12 Bayer Aktiengesellschaft Regulation du recepteur ta5 humain
WO2002101043A2 (fr) * 2001-06-08 2002-12-19 Bayer Aktiengesellschaft Regulation du recepteur ta4 humain

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 7 October 1997 (1997-10-07), XP002263280 *
ZENG Z ET AL: "Cloning of a putative human neurotransmitter receptor expressed in skeletal muscle and brain", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 242, no. 3, AF021818, 1998, pages 575 - 578, XP002116644, ISSN: 0006-291X *

Also Published As

Publication number Publication date
WO2004008153A2 (fr) 2004-01-22
AU2003244637A1 (en) 2004-02-02

Similar Documents

Publication Publication Date Title
WO2004008153A3 (fr) Diagnostique et therapie des maladies associees au recepteur presume de neurotransmetteurs chez l'humain (pnr)
WO2005040828A3 (fr) Agents de diagnostic et de traitement des maladies associees au recepteur 49 couple aux proteines g (gpr49)
WO2004082568A3 (fr) Diagnostics et traitements contre des maladies associees au recepteur 5a du composant du complement (c5ar)
WO2004038405A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 43 couple a la proteine g (gpr43)
WO2005095972A3 (fr) Composes destines au diagnostic et au traitement de maladies associees au recepteur couple aux proteines g etb (etb)
WO2004104577A3 (fr) Approches diagnostiques et therapeutiques des maladies associees au recepteur 5-hydroxytryptamine 4 (5-ht4)(serotonine)
WO2004071378A3 (fr) Methodes diagnostiques et therapeutiques relatives a des etats pathologiques lies au recepteur hm74a couple a la proteine g
WO2003095967A3 (fr) Methodes diagnostiques et therapeutiques pour les maladies associees au recepteur 9 des chimiokines (ccr9)
WO2003080098A3 (fr) Diagnostics et therapeutiques associes au recepteur 2 du peptide de formyle humain
WO2005106489A3 (fr) Diagnostics et therapies s'appliquant a des maladies associees aux recepteurs 5 des chimiokines c-c (ccr5)
WO2004038421A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 41 couple a une proteine g humaine (gpr41)
WO2004086034A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur adenosine a3 couple a la proteine g (adora3)
WO2003066077A3 (fr) Outil de diagnostic et therapeutique pour des maladies associees au recepteur de neuromedine u1 (nmu1)
WO2004082571A3 (fr) Diagnostics et therapies pour maladies associees au recepteur 86 couple a la proteine g (gpr86)
WO2004082566A3 (fr) Methodes diagnostiques et therapeutiques de maladies associees au recepteur 1 du composant de complement 3a (c3ar1)
WO2003080097A3 (fr) Methodes diagnostiques et therapeutiques relatives a des maladies associees au recepteur 7 couple a la proteine g humaine (gpr7)
WO2003096020A3 (fr) Diagnostic et traitement de maladies liees au recepteur 8 des chimiokines (ccr8)
WO2004057328A3 (fr) Diagnostics et traitements pour les maladies associees au recepteur couple a la proteine g 38 (gpr38)
WO2003081234A3 (fr) Methodes diagnostiques et therapeutiques relatives a des maladies associees au recepteur 8 couple a la proteine g humaine (gpr8)
WO2004044589A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur 3 couple a une proteine g sphingolipide de differenciation endotheliale humain (edg3)
WO2004082572A3 (fr) Diagnostics et therapies pour les maladies associees au recepteur 87 couple a la proteine g (gpr87)
WO2004038416A8 (fr) Diagnostic et therapeutique de maladies associees au recepteur 6 couple a la proteine g humain (gpr6)
WO2004038407A3 (fr) Diagnostics et medicaments pour maladies associees au recepteur 12 humain couple a la proteine g (gpr12)
WO2004086047A3 (fr) Agents diagnostiques et therapeutiques de maladies associees a adenosine a1 du recepteur couple a la proteine g (adora1)
WO2004071392A8 (fr) Agents de diagnostic et de traitement destines aux maladies associees au recepteur acetylcholine, muscarinique 4(m4)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载